Pfizer says its vaccine is 95% effective, will apply to FDA for emergency use 'within days'
The company could have 50 million doses ready before January
Pfizer Inc. said Wednesday that its coronavirus vaccine is 95% effective and does not cause any serious side effects following injection.
The data, which comes from the company's first complete set of results following its Phase 3 trial, indicates that the vaccine prevents mild and serious forms of the novel illness and is 94% effective in elderly patients, who are more susceptible to serious forms of the virus.
The company says it plans to apply to the Food and Drug Administration for emergency use authorization "within days."
If the FDA approves the two-dose vaccine, Pfizer says it may be able to produce as many as 50 million doses by the end of 2020, and up to 1.3 billion by the end of the following year.
News, Not Noise
- WHO probe into COVID origins taps scientist who funneled NIH grants to suspect Wuhan lab
- Declassified memos detail effort to get McCabe to step aside in Russia probe over conflict
- Kremlin says U.S. interfered in Russian affairs by condemning harsh tactics over Navalny protests
- Sidney Powell announces forming of 'Restore the Republic PAC'
- Supreme Court dismisses suits against Trump alleging he illegally accepted foreign gifts